Cadonilimab, a medication targeting PD-1 and CTLA-4, demonstrates efficacy in treating various types of cancer, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, and nasopharyngeal cancer [84,85]. Here, PDCD1 is linked to cancer.